Softwr

Healthcare · head to head

Allscripts vs Therapixel

Allscripts logo

Allscripts

Healthcare

Healthcare IT solutions for care coordination

From
On request
Rated
-
Full reviewWebsite
Therapixel logo

Therapixel

Healthcare

French mammography AI with FDA clearances for 2D and tomosynthesis breast screening

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Allscripts pricing is not publicly available; all quotes require direct contact with sales; Therapixel european and American regulatory positions were established under different regimes, and under the EU Medical Device Regulation this class of diagnostic AI faces a higher classification and notified body scrutiny, so European buyers must verify the current MDR certificate and expiry rather than relying on a legacy CE reference.
  • They diverge on capability: Allscripts covers Electronic Health Records, Therapixel covers MammoScreen 2D.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Allscripts and Therapixel actually diverge.

Attributes where Allscripts and Therapixel differ
AttributeAllscriptsTherapixel
Founded1986Unknown

Identical on both: starting price (On request), pricing model (quote), free tier (No), platforms (Web), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Allscripts

  • Electronic Health Records
  • Practice Management
  • Population Health
  • Care Coordination
  • Analytics
  • HL7
  • FHIR
  • Labs

Only in Therapixel

  • MammoScreen 2D
  • MammoScreen DBT
  • One to ten suspicion score
  • Summary report
  • Workstation and PACS delivery
  • Reading workflow configurations

What people use each for

The jobs each tool is most often brought in to do.

Allscripts

  • Electronic health records and practice management for healthcare providersnot Therapixel
  • Healthcare IT solutions for revenue cycle management and patient engagement (now Veradigm)not Therapixel

Therapixel

  • A European breast screening programme running mandatory double reading that wants to evaluate AI as a concurrent or second reader within what national guidance permitsnot Allscripts
  • An American breast centre that has moved to tomosynthesis and needs reading support on DBT specifically, which Therapixel holds a clearance fornot Allscripts
  • A screening service wanting a graded suspicion score rather than a binary flag so readers can calibrate their own thresholdnot Allscripts
  • A radiology group evaluating multiple mammography AI vendors head to head on their own historic case set before committingnot Allscripts

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Allscripts

  • Pricing is not publicly available; all quotes require direct contact with sales
  • Transitioned to Veradigm brand in 2022; legacy Allscripts product line integrated into Veradigm suite

Therapixel

  • European and American regulatory positions were established under different regimes, and under the EU Medical Device Regulation this class of diagnostic AI faces a higher classification and notified body scrutiny, so European buyers must verify the current MDR certificate and expiry rather than relying on a legacy CE reference.
  • MammoScreen does mammography only, so a hospital wanting AI across head CT, chest and breast needs several vendors and several PACS integrations, or an orchestration layer bought from someone else.
  • Therapixel is a small French company competing against Hologic and iCAD, which have incumbency inside the mammography reading workstation, so integration into an American breast centre is more work than it is for the workstation vendor own AI.
  • Detection performance is sensitive to the mammography unit vendor and acquisition protocol, so published results do not transfer between estates and each site needs local validation it must fund itself.
  • Whether AI can substitute for one of two human readers is a national workforce and liability question, not a product capability, so the labour saving that justifies the purchase in one country is not permitted in another.

Pricing, plan by plan

Allscripts

On request

No published plan breakdown. See the Allscripts review.

Therapixel

On request
  • MammoScreen$undefined/year
    • Priced per examination or by annual screening volume
    • 2D and tomosynthesis licensed by the versions cleared for each
    • Cloud or on premises deployment quoted differently

Which should you pick?

Choose Allscripts if

  • You need electronic health records.
  • You also want practice management.
Allscripts review

Choose Therapixel if

  • You need mammoscreen 2d.
  • You also want mammoscreen dbt.
Therapixel review

Questions people ask

Is Allscripts or Therapixel better?
Neither clearly leads. Allscripts starts at On request and Therapixel at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Allscripts or Therapixel?
Allscripts starts at On request and Therapixel at On request.
Does Allscripts or Therapixel run on more platforms?
Both run on Web, so platform support will not decide this one for you.
What is Allscripts best used for?
Allscripts is most often used for electronic health records and practice management for healthcare providers, healthcare it solutions for revenue cycle management and patient engagement (now veradigm). Of those, electronic health records and practice management for healthcare providers and healthcare it solutions for revenue cycle management and patient engagement (now veradigm) are not what Therapixel is typically brought in for.
What can Allscripts do that Therapixel cannot?
Allscripts covers Electronic Health Records, Practice Management, Population Health, Care Coordination. Therapixel covers MammoScreen 2D, MammoScreen DBT, One to ten suspicion score, Summary report.

Answered from the vendors’ own pages

Allscripts: How do I obtain pricing information for Veradigm solutions?

Veradigm does not publish pricing on their website. Interested buyers must contact a Veradigm Account Executive directly or request a demo to discuss pricing and licensing options tailored to their needs.

Source
Therapixel: Is MammoScreen FDA cleared?

Yes. It holds 510(k) clearance K192854 for two dimensional mammography from July 2020, a November 2021 clearance for digital breast tomosynthesis, and two further clearances in October 2024 for later versions.

Allscripts: What industries does Veradigm serve?

Veradigm serves four primary market segments: Healthcare Providers, Life Sciences companies, Health Plans and Payers, and Health IT Vendors. Each segment has specialized solutions.

Source
Therapixel: Is it CE marked?

Yes, but European buyers should ask specifically for the current certificate under the Medical Device Regulation and its expiry date, because this class of diagnostic AI moved to a higher classification under MDR.

Allscripts: Is there a trial available for Veradigm solutions?

Veradigm offers the option to request a demo of their solutions, which is the primary way potential customers can evaluate the platform before making a purchasing decision.

Source
Therapixel: What does the one to ten score mean?

It is a graded suspicion score per finding and per study, designed to be integrated alongside a radiologist BI-RADS assessment rather than treated as a positive or negative result.

Therapixel: Does it cover anything besides mammography?

No. It is a mammography product only, including tomosynthesis. Other body regions need a different vendor.

Share

Related pages

More on Allscripts

More on Therapixel

Keep looking

Other head to heads